JenaValve Technology has raised $4.9 million in a new round of debt financing, according to an SEC filing posted this week.
The Irvine, Calif.-based company is one of several smaller players looking to enter the transcatheter aortic valve implant space as it challenges major players Edwards Lifesciences (NYSE:EW), Medtronic (NYSE:MDT), Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX).
JenaValve has not yet stated how it plans to spend funds raised in the round, but is not seeking any more funds.
Money in the round comes from 11 anonymous sources, with the first sale recorded on Jan. 23, according to the filing.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.